Results 251 to 260 of about 20,100 (304)

Switch from eculizumab to satralizumab in aquaporin 4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder: a case series report. [PDF]

Front Immunol
Abboud H, Subei A, Sengul B, Shin RK, Goulette P, Walch R, Coté J, Pace R, Obeidat AZ, Ferayorni L, Gholizadeh S.   +10 more
europepmc   +1 more source

Clinical Outcomes and Treatment Strategies of Adult Transplant-Associated Thrombotic Microangiopathy: External Validation of Harmonizing Definitions and High-Risk Criteria. [PDF]

Am J Hematol
Acosta-Medina AA, Sridharan M, Go RS, Moyer AM, Leung N, Willrich MAV, Wolf R, Kassis R, Manasrah A, Kohorst MA, Durani U, Matin A, Hefazi M, Kenderian SJ, Mangaonkar AA, Shah MV, Litzow MR, Hogan WJ, Dingli D, Alkhateeb HB.   +19 more
europepmc   +1 more source

Adverse drug events (ADEs) risk signal mining related to eculizumab based on the FARES database. [PDF]

Front Pharmacol
Wang XF, Bao LR, Hu TL, Xu RF, Gao WN, Wang JY, Zhao JR, Fu ZL, Meng Y, Wang SF.   +9 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Prospective Multi-Institutional Study of Eculizumab to Treat High-Risk Stem Cell Transplant Associated TMA.

Blood, 2023
High-risk, complement mediated, untreated transplant-associated thrombotic microangiopathy (hrTMA) has dismal outcomes due to multi-organ dysfunction (MODS).
S. Jodele, C. Dandoy, P. Aguayo-Hiraldo, A. Lane, Ashley Teusink‐Cross, Anthony Sabulski, Kana Mizuno, B. Laskin, J. L. Freedman, Stella M. Davies   +9 more
semanticscholar   +1 more source

Eculizumab in renal transplantation [PDF]

Transplantation Reviews, 2013
Antibody-mediated rejection, be it acute, subacute or chronic, is currently recognized as the major cause of graft loss in kidney transplant recipients. Anti-HLA donor-specific antibodies are deleterious to the graft fate whether they pre-exist to the transplantation or appear in the course of transplantation.
Christophe Legendre, Christophe Legendre, Marc-Olivier Timsit, Marc-Olivier Timsit, Dany Anglicheau, Dany Anglicheau, Julien Zuber, Julien Zuber, Rebecca Sberro-Soussan, Rebecca Sberro-Soussan, Alexandre Loupy, Alexandre Loupy, Marion Rabant, Marion Rabant   +13 more
openaire   +2 more sources

Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience.

European Review for Medical and Pharmacological Sciences, 2020
OBJECTIVE SARS-CoV-2 (Severe Acute Respiratory Syndrome Coronavirus 2)-related pneumonia, referred to as COVID-19 (Coronavirus Disease 19), is a public health emergency as it carries high morbidity, mortality, and has no approved specific pharmacological
F. Diurno, F. Numis, G. Porta, F. Cirillo, S. Maddaluno, A. Ragozzino, P. Negri, C. Gennaro, A. Pagano, E. Allegorico, L. Bressy, G. Bosso, A. Ferrara, C. Serra, A. Montisci, M. D’Amico, S. Morello, G. D. Costanzo, A. Tucci, P. Marchetti, U. D. Vincenzo, I. Sorrentino, A. Casciotta, M. Fusco, C. Buonerba, M. Berretta, Manuela Ceccarelli, G. Nunnari, Y. Diessa, S. Cicala, G. Facchini   +30 more
semanticscholar   +1 more source

The use of eculizumab in renal transplantation

Clinical Transplantation, 2013
AbstractThe complement system plays a vital role in mediating disease processes within renal allografts. Eculizumab is a humanized monoclonal antibody that targets complement protein C5, inhibiting cleavage into C5a and C5b, and therefore preventing formation of the membrane attack complex (MAC).
Anthony Dorling, Nizam Mamode
exaly   +5 more sources

Eculizumab and Temsirolimus

Hospital Pharmacy, 2007
The increasing complexity of cancer chemotherapy now requires that pharmacists be familiar with these highly toxic agents. This column will review various issues related to preparation, dispensing, and administration of cancer chemotherapy, and review various agents, both commercially available and investigational, used to treat malignant diseases ...
Dominic A. Solimando, J. Aubrey Waddell, Katherine B. Worley, M. Brooke Whitmore   +3 more
openaire   +2 more sources

Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10‐year pharmacovigilance analysis

British Journal of Haematology, 2019
Eculizumab is the first and only medication approved for paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS) treatment. However, eculizumab safety based on long‐term pharmacovigilance is unknown.
Gérard Soci, Peter Hillmen, Johan Vande Walle   +2 more
exaly   +2 more sources